A 10-day microlearning course may help pharmacists decode genetic data for safer prescriptions
NCT ID NCT07735572
First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This trial tests whether a brief, Arabic-language microlearning program can improve community pharmacists' ability to use pharmacogenomic information — how a person's genes affect their response to drugs — in their daily practice. About 150 licensed pharmacists in Jordan will take the program over 10 days, covering topics like interpreting genetic test results for the blood thinner clopidogrel. Researchers will measure changes in decision-making, knowledge, and confidence immediately after the program and again four weeks later.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Arabic CPIC-based pharmacogenomics microlearning program
- What this could lead to
- If effective, this program could help pharmacists worldwide better interpret genetic data to improve medication safety and effectiveness.
- What could go wrong
- This is a small, single-country trial with a short follow-up. Results may not apply to other settings or translate into lasting changes in practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
150 people
The number who actually took part.
- Started
-
Mar 2026
- Finished
-
Jul 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participants had to be licensed pharmacists working in a community pharmacy in Jordan * Participants had to be capable of comprehending the Arabic language * Participants have access to internet-enabled devices (smartphones, tablets, computers) * Participants give informed consent electronically and agree to take all assessments longitudinally (baseline, immediate post-intervention, and follow-up four weeks later). Exclusion Criteria: * Participants having an advanced postgraduate specialty or previous training in PGx (This criteria helps eliminate the problem of ceiling effect in order to evaluate the intervention as intended for a specific target audience: community pharmacists without advanced precision medicine training.) * Participants being involved in PGx research, curriculum development, and/or delivering PGx services * Participants providing incomplete baseline surveys * Participants withdrawing from the study before randomization. These exclusions were purposefully designed to mitigate baseline expertise bias and ensure the sample accurately reflects the broader, non-specialized community pharmacy workforce.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pharmacogenomics are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Petra University
Amman, Amman Governorate, Jordan